New research offers more evidence for the connection between CYP2C9 and VKORC1 variants and increased bleeding risk in patients taking warfarin. A large-scale study published in the March edition of the Lancet found that atrial fibrillation patients whose CYP2C9 and VKORC1 genetic variations made them highly sensitive to warfarin were nearly three times more likely to experience bleeding than those … Read More